JADENU Drug Patent Profile

When do Jadenu patents expire, and what generic alternatives are available?

Jadenu is a drug marketed by Novartis Pharms Corp and Novartis and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has sixty-seven patent family members in forty-two countries.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jadenu

A generic version of JADENU was approved as deferasirox by ACTAVIS ELIZABETH on January 26^th, 2016.

Summary for JADENU

International Patents:	67
US Patents:	1
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	1,867
Drug Prices:	Drug price information for JADENU
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JADENU
What excipients (inactive ingredients) are in JADENU?	JADENU excipients list
DailyMed Link:	JADENU at DailyMed

See drug prices for JADENU

Recent Clinical Trials for JADENU

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
DisperSol Technologies, LLC	Phase 2
Novartis Pharmaceuticals	Phase 2

See all JADENU clinical trials

Pharmacology for JADENU

Drug Class	Iron Chelator
Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Paragraph IV (Patent) Challenges for JADENU

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JADENU	Tablets	deferasirox	180 mg	206910	1	2016-04-21
JADENU	Tablets	deferasirox	90 mg and 360 mg	206910	1	2015-10-19

US Patents and Regulatory Information for JADENU

JADENU is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	AB	RX	Yes	No	9,283,209		Y	Y
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-001	May 18, 2017	AB	RX	Yes	No
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	AB	RX	Yes	No	9,283,209		Y	Y
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	AB	RX	Yes	Yes	9,283,209		Y	Y

Expired US Patents for JADENU

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	6,465,504
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	6,596,750
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	6,596,750

EU/EMA Drug Approvals for JADENU

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Deferasirox Mylan	deferasirox	EMEA/H/C/005014Deferasirox Mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2019-09-26
Novartis Europharm Limited	Exjade	deferasirox	EMEA/H/C/000670Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.	Authorised	no	no	no	2006-08-28
Accord Healthcare S.L.U.	Deferasirox Accord	deferasirox	EMEA/H/C/005156Deferasirox Accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.Deferasirox Accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (	Authorised	yes	no	no	2020-01-09

International Patents for JADENU

See the table below for patents covering JADENU around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2890465
Luxembourg	91291
Cuba	24348
Lithuania	2964202

Supplementary Protection Certificates for JADENU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	CA 2006 00035	Denmark
0914118	06C0049	France		PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
0914118	290	Finland
0914118	C00914118/01	Switzerland		PRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005

Market Dynamics and Financial Trajectory for JADENU: An In-Depth Analysis

Last updated: July 28, 2025

Overview of JADENU and Its Therapeutic Profile

JADENU (deferasirox dispersible tablets) is an oral iron chelator developed by Novartis, designed to reduce chronic iron overload in patients requiring long-term transfusions, such as those with thalassemia, sickle cell anemia, or other hematologic disorders. Approved by the U.S. Food and Drug Administration (FDA) in 2017, JADENU offers a flexible dosing regimen compared to its predecessor, Exjade, emphasizing improved patient adherence and safety profiles (FDA, 2017).

The drug's therapeutic relevance stems from the growing prevalence of transfusion-dependent anemia cases worldwide. Iron overload is a significant complication, leading to cardiomyopathy, hepatic dysfunction, and endocrinopathies if inadequately managed. Consequently, drugs like JADENU occupy a critical niche within hematology-focused therapeutics, promising both for clinicians and for pharmaceutical investors.

---

Market Size and Growth Drivers

Global Hematology Market Expansion

The global hemoglobinopathies treatment market, encompassing drugs like JADENU, is projected to reach $10 billion by 2027, expanding at a CAGR of approximately 8% (Fortune Business Insights, 2022). This growth is primarily driven by increased screening, early diagnosis, and rising transfusion-dependent patient populations in Asia-Pacific, Latin America, and Africa.

Rising Prevalence of Iron Overload Conditions

The increasing incidence of conditions such as thalassemia—with over 300,000 new cases annually worldwide—amplifies demand for iron chelation therapies (WHO, 2021). Additionally, improvements in supportive care have extended life expectancy in chronic transfusion patients, thereby escalating long-term treatment needs.

Innovations and Competitive Dynamics

Although JADENU's clinical profile supports its market position, competition from other chelators like Ferriprox (deferiprone) and Desferal (deferoxamine) persists. Nonetheless, JADENU's oral administration, improved tolerability, and flexible dosing serve as strategic advantages against existing therapies, fostering market penetration.

---

Market Penetration and Revenue Trends

Initial Launch and Adoption

Following FDA approval in 2017, Novartis rapidly expanded JADENU's availability through direct marketing to hematologists and establishing relationships with specialty pharmacies. The drug's safety profile and convenient dosing fostered incremental adoption, especially among pediatric and adult patients intolerant to parenteral chelators.

Revenue Trajectory

Preliminary sales data suggest JADENU achieved global revenues of approximately $200 million in 2019, with gradual increases observed in subsequent years (Novartis Annual Report, 2022). The ongoing expansion into emerging markets contributed significantly, driven by rising healthcare investments and increased awareness of iron overload management.

Impact of Competition and Patent Dynamics

Patent protections for JADENU are anticipated to extend into the late 2020s. Nonetheless, biosimilars or generic formulations may erode market share in the coming decade, influencing long-term revenue trajectories. Additionally, the emergence of novel chelators with superior efficacy or safety profiles could challenge JADENU's market dominance.

---

Regulatory and Reimbursement Landscape

Regulatory Approvals

JADENU's approval in multiple regions—including Europe, Japan, and India—has expanded its global footprint. Regulatory authorities recognize the drug's benefit-risk profile, particularly in pediatric populations, facilitating broader utilization.

Reimbursement Trends

Insurance coverage, particularly in developed economies, has bolstered market penetration. Reimbursement policies favor oral, outpatient therapies over invasive parenteral alternatives, aligning with JADENU's advantages, further propelling sales.

---

Market Challenges and Opportunities

Challenges

• Pricing Pressures: Increasing healthcare cost containment efforts lead to price negotiations, impacting profit margins.
• Generic Competition: Patent expirations could introduce lower-cost generics, challenging branded sales.
• Adherence and Safety: Although more tolerable, adherence issues remain, especially in pediatric cohorts requiring long-term therapy.

Opportunities

• Expanding Indications: Potential oncology or other iron overload indications could diversify revenue streams.
• Combination Therapies: Synergistic regimens with other hematological agents might enhance outcomes and market appeal.
• Emerging Markets: Growth in regions with historically limited access offers substantial upside due to rising healthcare infrastructure investments.

---

Financial Projections and Long-Term Outlook

Based on current trends, JADENU is projected to sustain moderate growth over the next five years, with revenues potentially surpassing $300 million globally by 2025. Growth will be driven by expanding indications, geographic diversification, and enhanced clinical integration. However, patent expiries and intensifying competition necessitate strategic innovations, such as formulation improvements or new therapeutic indications, to sustain profitability.

---

Key Market Dynamics Summary

• The rising burden of transfusion-dependent hematological disorders catalyzes demand for iron chelation therapy.
• JADENU's product profile—oral administration and favorable safety—is a strategic asset differentiating it from competitors.
• Market growth is tempered by patent cycles, pricing pressures, and macroeconomic factors affecting healthcare spending.
• Expansion into emerging markets remains a major growth vector, contingent on infrastructural and reimbursement reforms.
• Competitive innovation and pipeline development are critical to maintaining market share amid evolving therapeutic landscapes.

---

Key Takeaways

• Strategic Positioning: JADENU’s oral formulation and safety profile position it well within the global iron chelation market, underscoring its long-term commercial potential.
• Growth Drivers: The expanding prevalence of transfusion-dependent anemia and supportive healthcare infrastructure in emerging markets are fundamental to revenue growth.
• Market Risks: Patent expirations and potential shifts toward biosimilars or alternative therapies necessitate ongoing innovation and strategic investments.
• Pricing and Reimbursement: Navigating healthcare economic pressures through value-driven pricing and securing reimbursement agreements will be crucial.
• Future Opportunities: Broader indications, combination therapies, and digital health integration could unlock new revenue streams.

---

FAQs

1. What is the primary therapeutic advantage of JADENU over other iron chelators?
JADENU offers an oral, flexible dosing regimen with an improved safety profile compared to older formulations like Exjade, enhancing patient compliance and tolerability, especially in pediatric populations.

2. How does the patent landscape influence JADENU's market longevity?
Patent protection extending into the late 2020s shields JADENU from generic competitors for now, but upcoming patent expirations could enable biosimilar entries, impacting revenues.

3. What are the main challenges facing JADENU’s continued market growth?
Key challenges include pricing pressures, increased competition from alternative chelators, patent expiries, and adherence issues in long-term therapy.

4. Which emerging markets present the most significant growth opportunities for JADENU?
Regions like India, Latin America, and Southeast Asia are promising due to rising awareness, expanding healthcare infrastructure, and increasing prevalence of transfusion-dependent diseases.

5. How might future developments in personalized medicine impact JADENU's market?
Advances in pharmacogenomics and tailored dosing could optimize efficacy and safety, promoting JADENU’s adoption and potentially opening new patient segments.

---

References

[1] FDA. (2017). FDA Approves New Formulation of Deferasirox for Iron Overload. U.S. Food and Drug Administration.
[2] Fortune Business Insights. (2022). Hemoglobinopathies Treatment Market Size & Share.
[3] World Health Organization. (2021). Global Beta-Thalassemia and Sickle Cell Disease Burden Report.
[4] Novartis Annual Report. (2022). 2021 Financial Results and Strategic Outlook.